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The Peroxisome Proliferator-Activated Receptor-
Agonist Pioglitazone Represses Inflammation in a
Peroxisome Proliferator-Activated Receptor-–
Dependent Manner In Vitro and In Vivo in Mice
Gabriela Orasanu, MD,*‡ Ouliana Ziouzenkova, PHD,*‡ Pallavi R. Devchand, PHD,*‡
Vedika Nehra, MS,*‡ Osama Hamdy, MD,†‡ Edward S. Horton, MD,†‡ Jorge Plutzky, MD*‡
Boston, Massachusetts
Objectives Our aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)- agonist pioglitazone modu-
lates inflammation through PPAR mechanisms.
Background The thiazolidinediones (TZDs) pioglitazone and rosiglitazone are insulin-sensitizing PPAR agonists used to treat
type 2 diabetes (T2DM). Despite evidence for TZDs limiting inflammation and atherosclerosis, questions exist
regarding differential responses to TZDs. In a double-blinded, placebo-controlled 16-week trial among recently
diagnosed T2DM subjects (n  34), pioglitazone-treated subjects manifested lower triglycerides and lacked the
increase in soluble vascular cell adhesion molecules (sVCAM)-1 evident in the placebo group. Previously we re-
ported PPAR but not PPAR agonists could repress VCAM-1 expression. Since both triglyceride-lowering and
VCAM-1 repression characterize PPAR activation, we studied pioglitazone’s effects via PPAR.
Methods Pioglitazone effects on known PPAR responses—ligand binding domain activation and PPAR target gene ex-
pression—were tested in vitro and in vivo, including in wild-type and PPAR-deficient cells and mice, and com-
pared with the effects of other PPAR (rosiglitazone) and PPAR (WY14643) agonists.
Results Pioglitazone repressed endothelial TNF-induced VCAM-1 messenger ribonucleic acid expression and promoter
activity, and induced hepatic IB in a manner dependent on both pioglitazone exposure and PPAR expression.
Pioglitazone also activated the PPAR ligand binding domain and induced PPAR target gene expression, with
in vitro effects that were most pronounced in endothelial cells. In vivo, pioglitazone administration modulated
sVCAM-1 levels and IB expression in wild-type but not PPAR-deficient mice.
Conclusions Pioglitazone regulates inflammatory target genes in hepatic (IB) and endothelial (VCAM-1) settings in a
PPAR-dependent manner. These data offer novel mechanisms that may underlie distinct TZD
responses. (J Am Coll Cardiol 2008;52:869–81) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.055a
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ihe increased risk for atherosclerotic complications evident
n individuals with type 2 diabetes mellitus (T2DM) has
riven interest in the cardiovascular effects of antidiabetic
herapies both in use and under development (1,2). The
umber of insulin resistance-associated abnormalities that
rom the *Cardiovascular Division, Brigham and Women’s Hospital; †Clinical
esearch Center, Joslin Diabetes Center; and ‡Harvard Medical School, Boston,
assachusetts. Dr. Plutzky has received grant support from the National Institutes of
ealth (R01 HL071745). The clinical trial presented here was supported by Takeda
harmaceuticals (Dr. Horton, primary investigator). The investigators have received
rior funding from GlaxoSmithKline and Takeda Pharmaceuticals, although not
pecifically for the support of the pre-clinical murine studies included here.t
Manuscript received March 10, 2008; revised manuscript received April 22, 2008,
ccepted April 29, 2008.lso promote atherosclerosis focused attention on the cardio-
ascular effects of insulin-sensitizing agents (3). In this context,
hiazolidinediones (TZDs) held significant promise as insulin
ensitizers that lower glucose and reportedly limited athero-
clerosis and inflammation in vitro and in vivo in both mice
nd humans (4). Recently, the TZDs pioglitazone and rosigli-
azone have been scrutinized for their possible distinct effects,
ncluding those on the cardiovascular system (5).
See page 882
TZDs bind to and activate PPAR, a ligand-activated
ranscription factor that regulates key metabolic pathways,
ti
p
v
i
t
P
v
(
P
t
m
s
p
P
P
fi
h
a
M
H
A
p
m
d
e
p
i
fi
t
s
m
p

u
e
t
c
d
p
a
c
s
o
i
P
t
w
a
s
p
i
a
l
m
L
f
(
w
(
a
l
d
u
m
(
(
R
870 Orasanu et al. JACC Vol. 52, No. 10, 2008
Pioglitazone in PPAR Pathways September 2, 2008:869–81including adipogenesis and insulin
sensitivity (6,7). Pioglitazone and
rosiglitazone are approved as
“highly selective” peroxisome
proliferator-activated receptor
(PPAR)- agonists (8). PPAR
is also expressed in vascular and
inflammatory cells where its acti-
vation can regulate target genes
relevant to atherosclerosis (9). Al-
though pioglitazone and rosiglita-
zone target the same PPAR iso-
form (4), recent human TZD data
have raised the possibility of vari-
able responses between these
agents as well as with other
PPAR agonists. In several stud-
ies, including one head-to-head
clinical trial, pioglitazone and ros-
iglitazone have had variable as well
as divergent effects on triglycerides
(TG) (10,11). Meta-analysis data
have suggested possible adverse
cardiovascular outcomes with ros-
iglitazone (12–14), although not
without controversy (15,16); simi-
lar studies with pioglitazone have
not shown cardiovascular safety
signals, including one prospective
clinical trial (13,17). Novel dual
PPAR/ agonists in develop-
ment have been abandoned for
various adverse effects, including
cardiovascular responses (12), rais-
ing concerns about dual PPAR/
therapeutics (18,19). Clearly, addi-
tional mechanistic insight into
how specific PPAR agonists exert
heir effects is needed.
During a small 16-week study on inflammatory markers
n patients with recently diagnosed T2DM randomized to
ioglitazone or placebo, we noted that levels of soluble
ascular cell adhesion molecule (sVCAM)-1, an early player
n atherogenesis, increased in the placebo group but not in
he group on pioglitazone (20). Previously we reported that
PAR activation had no effect on VCAM-1 expression in
itro, although those studies did not include pioglitazone
21). In contrast, PPAR agonists decrease VCAM-1 in a
PAR-dependent manner (22). Although limited in na-
ure, this clinical data raised the hypothesis that pioglitazone
ight repress inflammation, including VCAM-1 expres-
ion, in part via PPAR. Although previously raised as a
ossibility, we studied pioglitazone effects on known
PAR responses in more definitive models, including
PAR-deficient cells and mice (23). We provide here the
Abbreviations
and Acronyms
ACO  acyl-CoA oxidase
BAEC  bovine aortic
endothelial cells
EC  endothelial cell
FPG  fasting plasma
glucose
GAPDH  glyceraldehyde-3-
phosphate dehydrogenase
HbA1c  hemoglobin A1c
HDL  high-density
lipoprotein
HSVEC  human
endothelial cells isolated
from saphenous vein
LBD  ligand binding
domain
LDL  low-density
lipoprotein
LPL  lipoprotein lipase
LPS  lipopolysacharide
PPAR  peroxisome
proliferator-activated
receptor
TG  triglyceride(s)
TNF  tumor necrosis
factor
TZD  thiazolidinedione
T2DM  type 2 diabetes
mellitus
VCAM  vascular cell
adhesion molecule
2h-OGTT  2-h plasma
glucose >200 mg/dl
during oral glucose
tolerance testingrst evidence that pioglitazone represses key endothelial and wepatic inflammatory responses in vitro and in vivo in mice in
PPAR-dependent manner.
ethods
uman studies. SUBJECTS. Individuals meeting the
merican Diabetes Association criteria for T2DM—fasting
lasma glucose (FPG) 126 mg/dl with a second confir-
atory measurement or a 2-h plasma glucose 200 mg/dl
uring oral glucose tolerance testing (2h-OGTT)—were
nrolled in a randomized, prospective, double-blinded,
lacebo-controlled clinical trial (n  34). The study cohort
ncluded subjects with newly diagnosed T2DM or con-
rmed T2DM on a nonpharmacological dietary interven-
ion for at least 4 weeks before the first study visit; all
ubjects were either drug-naïve or off any antidiabetic
edication for at least 4 weeks. Exclusion criteria included
rior TZD or insulin treatment, hemoglobin A1c (HbA1c)
10%; FPG 260 mg/dl; history of myocardial infarction,
nstable angina, cerebral vascular accident, transient isch-
mic attack, coronary artery bypass graft, or percutaneous
ransluminal coronary angioplasty; New York Heart Asso-
iation functional class III or IV congestive heart failure;
iastolic blood pressure 100 mm Hg and/or systolic blood
ressure 160 mm Hg; total cholesterol 300 mg/dl
nd/or TG 600 mg/dl; serum creatinine 1.5 mg/dl;
urrent use of systemic corticosteroids, immunosuppres-
ants, or androgens; any severe acute or chronic disease;
ther medical condition possibly interfering with study partic-
pation or assessment of the trial investigational products.
ROTOCOL. Participants, recruited from the Joslin Diabe-
es Center outpatient clinics or local media advertisement,
ere randomized 1:1 to either pioglitazone 30 mg tablet or
matching placebo once a day for the first 4 weeks, with a
ubsequent increase to pioglitazone 45 mg tablet or matched
lacebo once a day for the next 12 weeks (total 16 week
ntervention period). Both groups were evaluated at baseline
nd study conclusion. Patients were instructed on an isoca-
oric diet (50% carbohydrates, 20% protein, 30% fat) and to
aintain their usual physical activity.
ABORATORY EVALUATIONS. All measurements were per-
ormed at the Clinical Research Center, Joslin Diabetes Center
24). Plasma sVCAM-1 concentrations in mice and humans
ere determined in duplicate blinded samples using ELISA
Quantikine, R&D Systems, Minneapolis, Minnesota). Intra-
ssay variation was less than 10%; the sVCAM-1 detection
imit was 0.6 ng/ml. To analyze sVCAM-1 responses in
ifferent subgroups, national guideline cutpoint values were
sed: above and below FPG 126 mg/dl, 2h-OGTT 200
g/dl, HbA1c 7%, TG 150 mg/dl, low-density lipoprotein
LDL) cholesterol 100 mg/dl, high-density lipoprotein
HDL) cholesterol 40 mg/dl (25,26).
eagents. Pioglitazone hydrochloride (pioglitazone HCl)
as a gift from Takeda Pharmaceuticals North America
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September 2, 2008:869–81 Pioglitazone in PPAR PathwaysLincolnshire, Illinois); WY14643 (Biomol, Plymouth
eeting, Pennsylvania); rosiglitazone (BRL49653, Glaxo-
mithkline, Research Triangle Park, North Carolina). All
edia (BioWhittaker, Walkersville, Maryland) contained
ungizone, penicillin, streptomycin, and plasma as indi-
ated. Human and murine TNF were purchased from
&D Systems; Escherichia coli O111:B4 lipopolysacharide
LPS) and 2, 2, 2-tribromoethanol (Sigma-Aldrich, St.
ouis, Missouri).
ell culture. Human endothelial cells isolated from saphe-
ous veins (HSVECs) were cultured in M199 medium,
ndothelial cell (EC) growth factor, and 5% fetal calf serum
21). Bovine aortic endothelial cells (BAECs) were grown in
ulbecco modified Eagle medium (10% fetal bovine serum,
lutamine, penicillin, streptomycin, and fungizone) (27).
umor necrosis factor (TNF) stimulations were done at 10
g/ml. PPAR/ (129S1/SvImJ) mice were obtained from
ackson Laboratories (Bar Harbor, Maine). PPAR/ mice
129S4/SvJae) were a generous gift from F. Gonzalez (Na-
ional Institutes of Health). Murine ECs from 1-month-old
PAR/ and -/ mouse hearts were isolated using
ouble selection with intercellular adhesion molecule 2 and
latelet EC adhesion molecule 1 antibodies (BD PharMingen,
an Diego, California) bound to Dynabeads (Dynal, Lake
uccess, New York) as before (28).
lasmids. Human GAL4-PPAR- or -–ligand binding
omain (LBD) constructs (pSG5 vector, S. Kliewer, Uni-
ersity of Texas Southwestern, Dallas, Texas) were used for
ransactivation assays. The VCAM-1 promoter construct
755 upstream base pair [bp], T. Collins, Children’s Hos-
ital, Boston, Massachusetts) contains the major regulatory
lements (AP-1, NF-B, PPAR) (21). cDNA probes for
orthern blotting included human VCAM-1 (2.1kb Kpn/
phl fragment, G. Garcia-Cardena, Brigham and Women’s
ospital, Boston, Massachusetts); mouse full-length
PAR (2kb cDNA fragment); human acyl-CoA-oxidase
ACO; ATCC, Manassas, Virginia); and glyceraldehyde-3-
hosphate dehydrogenase (GAPDH) (ATCC).
ransient transfection assays. Standard GAL4-PPAR–
BD assays were performed as before (24-well plates, 2.5
04 BAECs/well, passage 2 to 5, FuGENE 6 (Roche
iagnostics, Indianapolis, Indiana) (27) in Dulbecco mod-
fied Eagle medium (1% delipidated fetal calf serum) using
uman GAL4-PPAR or --LBD, pUASx4-TK-luc, and
-galactosidase (pcDNA--Gal) constructs before stimula-
ion (24 h later) with the compounds indicated for 16 h. For
CAM-1 promoter studies, BAECs were plated in 1%
utridoma SP (Roche Diagnostics), transfected with the
CAM-1 promoter construct (24 h), and then pre-treated
ith pioglitazone (3 to 30 M) or WY14643 (25 to 225
M, 3 h) before TNF stimulation (12 h). Responses were
ormalized to co-transfected -galactosidase (pcDNA3)
ctivity using chlorophenol red--D-galactopyranoside
ubstrate (Roche Diagnostics) as before (27). For PPAR
econstitution experiments, murine PPAR/ ECs were
lated in 1% delipidated fetal calf serum before transfection sith either PPAR (mouse full-length PPAR-pSG5) or
mpty vector (pSG5, 24 h). Cells were pre-treated with
ioglitazone (10 M) or WY14643 (100 M) for 18 h
efore mouse TNF (10 h) stimulation as indicated.
ibonucleic acid extraction and Northern blot analysis.
otal ribonucleic acid was isolated using RNeasy (Qiagen,
alencia, California) before gel separation and transfer
Hybond-N, Amersham Pharmacia, Piscataway, New Jer-
ey). Northern and Western blots were quantitated using
ensitometry (Image-Pro Plus 5.1 software).
estern blotting. Standard Western blot analysis of hu-
an EC lysates were performed using rabbit polyclonal
ntibody against human IB (1:500, Santa Cruz Biotech-
ology, Santa Cruz, California) and monoclonal antibody
gainst GAPDH (1:10,000, Biodesign, Saco, Maine). For
n-vivo studies, frozen livers were pulverized, added to
IPA buffer (50 mM Tris, 150 mM NaCl, 1% Nonidet
-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
ulfate) with freshly added protease inhibitors, centrifuged
10’, 13,000 rpm, 4°C), and the protein extract boiled in
lectrophoresis buffer before gel separation (15% polyacryl-
mide, -mercaptoethanol-reducing conditions) and trans-
er (Immobilon-P membranes, semi-dry transfer, 1 h, 16
). After blocking (5% delipidated milk, 20 mM Tris, 55
M NaCl, 0.1% Tween 20, 1 h), immunoblotting with the
B and GAPDH antibodies described in the previous
ext was performed using chemiluminescence (PerkinElmer
ife Sciences, Boston, Massachusetts).
nimal studies. The 3-month-old age- and gender-
atched PPAR/ and PPAR/ mice were divided
nto 2 feeding groups (n  9/genotype). Group One
eceived pioglitazone (20 mg/kg body weight in 0.5% w/v
ethylcellulose) by gavage once daily for 7 days. Group
wo was treated similarly with vehicle (0.5% w/v methyl-
ellulose). Mice received free access to water, ordinary
aboratory diet, and standard animal care (Harvard Univer-
ity guidelines). On Day 1, mice received a survival dose of
nesthetic (2, 2, 2—tribromoethanol, 250 mg/kg body
eight) intraperitoneally before retro-orbital blood draw for
aseline serum measurements. On Day 8, retro-orbital
lood draws were repeated on a random subgroup of mice (n
5). The next day, all mice received LPS (12 mg/kg body
eight) intraperitoneally; 4 h later, mice were anesthetized
nd blood drawn by vena cava puncture and allowed to clot
vernight (4°C). Mice were then sacrificed and livers re-
oved immediately, rinsed (0.9% NaCl), and snap-frozen
or further analysis. Blood samples were centrifuged (2,000
g, 4°C, 20’) and serum sVCAM-1 concentrations deter-
ined in duplicate as described in the preceding text.
tatistical analysis. Statistical analysis, performed in con-
unction with the Brigham and Women’s Hospital Center
or Clinical Research Biostatistics Core Laboratory, em-
loyed Statistical Package for Social Sciences (version 16.0,
PSS Inc., Chicago, Illinois), SAS 9.1 (SAS Institute, Cary,
orth Carolina), and Analyze-it for Microsoft Excel (ver-ion 1.71). Results are presented as mean  SD or mean 
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Pioglitazone in PPAR Pathways September 2, 2008:869–81E. Means for baseline clinical characteristics of the human
tudy participants were compared using the independent
tudent t test. For within-group analysis (the baseline study
s. the follow-up assessment), 2-sided paired Student t test
or parametric data was used. For all other among-group
omparisons, the Mann-Whitney U test was used. Pearson
orrelation coefficients were calculated to test the association
etween variables. A value of p  0.05 was regarded as
ignificant.
esults
hanges in sVCAM-1 on pioglitazone versus placebo in
ecently diagnosed T2DM subjects. Pioglitazone (n 
9) and placebo (n  15) groups were similarly matched on
ll baseline variables, including sVCAM-1 levels (Table 1).
ioglitazone significantly improved FPG (162.2  13.6 vs.
25.4  7.1 mg/dl, p  0.002), 2h-OGTT (273.5  19 vs.
16.3  12.6, p  0.001), TG (160.7  24.9 vs. 129.1 
1.4, p  0.008), and TG/HDL ratio (3.5  0.5 vs. 3.1 
.2, p  0.02), all as compared with placebo at baseline
ersus study end (Table 1).
During the study, sVCAM-1 levels rose significantly in
atients with recently diagnosed T2DM randomized to
lacebo alone (baseline 512.1  45.7 ng/ml vs. study
onclusion 600.5  41.7 ng/ml, p  0.008, within-group
nalysis) (Table 1). In contrast, sVCAM-1 levels did not
ise among pioglitazone-treated subjects (baseline 470.4 
3.9 vs. conclusion 486.7  45.7 ng/ml, p  NS, within-
roup analysis) (Table 1). Using a mixed design linear
egression model to control for baseline levels of multiple
ubject Characteristics at Baseline and After 16 Weeks of Placebo
Table 1 Subject Characteristics at Baseline and After 16 Week
Placebo (n  15)
Baseline 16 Weeks
Age, yrs 58.8 11
Men/women 9/6
BMI, kg/m2 31.6 3.1 31.09 3
Weight, kg 94.1 9.7 93.3 9.1
Waist, cm 108.8 7.8
SBP, mm Hg 125.5 15.7
DBP, mm Hg 81.7 9.7
FPG, mg/dl 146.4 10.3 140.9 7.7
2h-OGTT, mg/dl 263.3 13.8 265.6 15.2
Total cholesterol, mg/dl 197.4 9.6 177.3 10.9
LDL-C, mg/dl 119 9.1 88.4 7.5
HDL-C, mg/dl 47 1.7 35 1.9
TG, mg/dl 169.8 15.3 150.3 16.1
TG/HDL ratio 3.5 0.3 4.6 0.6
sVCAM-1, ng/ml 512.1 45.7 600.5 41.7
hsCRP, mg/l 1.3† (0.44–3.89) 1.3† (0.49–89.3)
TNF, ng/ml 1.5 0.09 1.8 0.1
ata are shown as mean  standard error with 95% confidence interval or medial (†). No baseline
roup (paired Student t test); Median test (*) between groups pre- or post-treatment.
BMI  body mass index; DBP  diastolic blood pressure; FPG  fasting plasma glucose; HDL-C
ipoprotein cholesterol; OGTT  oral glucose tolerance test; SBP  systolic blood pressure; sVCAMarameters, only age had a significant impact on sVCAM-1 (evels (Online Table A). After controlling for age,
VCAM-1 levels differed significantly between placebo and
ioglitazone groups (p  0.03) (Online Table B). TNF
evels also increased over time from 1.5  0.09 to 1.8  0.1
g/ml in the placebo group but decreased from 1.3  0.08
o 1.2 0.08 ng/ml in the pioglitazone group, although not
n a statistically significant way. Baseline levels of high-
ensitivity C-reactive protein and sVCAM-1 were also
ignificantly correlated (r  0.45, p  0.02).
To generate hypotheses as to biologic mechanisms un-
erlying possible pioglitazone effects on repressing the
VCAM-1 increase seen in patients on placebo, responses
ere analyzed according to the intervention arm and sub-
roups stratified by accepted TG, HDL cholesterol, LDL
holesterol, FPG, and HbA1c cutpoints (see Methods sec-
ion). Only TG subgroups revealed differences in
VCAM-1 levels. Using the National Cholesterol Educa-
ion Program TG cutpoint of 150 mg/dl (29), significant
VCAM-1 increases were restricted to those with higher
aseline TG levels (150 mg/dl, n  9; from baseline 506
63.9 ng/ml to 683.1 56.4 ng/ml, p 0.03); sVCAM-1
evels did not differ significantly in placebo-treated subjects
ith lower baseline TG (150 mg/dl, n  6). Among
ioglitazone-treated subjects, sVCAM-1 levels did not
iffer in either higher or lower TG subgroups (data not
hown).
ioglitazone represses TNF-induced VCAM-1 mes-
enger ribonucleic acid (mRNA) expression in ECs.
iven the data above, we tested pioglitazone’s effects on
NF-induced VCAM-1 mRNA expression in HSVECs
ioglitazone
Placebo or Pioglitazone
Pioglitazone (n  19)
p Value Baseline 16 Weeks p Value
61.3 5.9
16/3
NS 31.9 3.7 32.1 3.5 NS
NS 95.8 13.7 96.6 12 NS
108.8 9.7
129.3 13.3
77.4 8.7
NS 162.2 13.6 125.4 7.1 0.002
NS 273.5 19 216.3 12.6 0.001
NS 203.8 9.9 169.2 7.4 NS
NS 128.4 8.3 103.1 7 NS
0.001 45.9 2.1 41.4 2.1 NS
NS 160.7 24.9 129.1 11.4 0.008
NS 3.5 0.5 3.1 0.2 0.02
0.008 470.4 33.9 486.7 45.7 NS
NS* 2.6† (0.25–23.8) 0.8† (0.17–8.75) NS*
NS 1.3 0.08 1.2 0.08 NS
nces in any variables (independent Student t test); p  0.05 shows significant differences within
h-density lipoprotein cholesterol; hsCRP  high sensitive C-reactive protein; LDL-C  low-density
ble vascular cell adhesion molecule; TG  triglycerides; TNF  tumor necrosis factor.or P
s of
differe18 h pre-treatment) using a concentration range commonly
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September 2, 2008:869–81 Pioglitazone in PPAR Pathwayssed in vascular biology studies which overlap pioglitazone
evels reported in humans (30). Pioglitazone inhibited
CAM-1 mRNA induction in a dose-dependent manner
Fig. 1A). For comparison, the known repression of
CAM-1 mRNA by the PPAR agonist WY14643 (100
M) is also shown (Fig. 1A). Quantification of relative
hanges in VCAM-1/GAPDH mRNA expression using
ensitometry reveals a significant pioglitazone effect at the
oncentrations shown (Fig. 1B) (3 to 30 M, p  0.05 for
ach). As previously reported, rosiglitazone (BRL49653,
RL) had no significant effect on VCAM-1 expression (data
ot shown) (21,31–33). Pioglitazone-mediated repression of
100

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Figure 1 Pioglitazone Reduces TNF-Induced VCAM-1 mRNA E
(A) Northern blot analysis of tumor necrosis factor (TNF)-induced vascular cell ad
formed on human saphenous vein endothelial cells (HSVECs) pre-treated in the ab
TNF stimulation (10 ng/ml, 10 h). The effects of the PPAR agonist WY14643 (1
shown. (B) The effect of the pioglitazone concentrations on VCAM-1/glyceraldehyd
seen in panel A (n  3, #p  0.05, TNF-induced vs. vehicle, *p  0.05, pioglitaz
pioglitazone exposure (10 M) on TNF-induced VCAM-1 expression was tested in
alone at 3 h, mean  SD (n  3; *p  0.05). (D) The effect of pioglitazone versu
endothelial cells before TNF stimulation are shown (left). For comparison, the ef
responses were normalized to -galactosidase (pCMV--Gal) (n  3 per each treat
alone, Mann-Whitney U test).CAM-1 expression also varied as a function of pioglitazone axposure (3, 6, 18 h; 10 M) before TNF stimulation
maximal 74% reduction at 18 h, p  0.05) (Fig. 1C).
We next considered if pioglitazone could inhibit human
CAM-1 promoter activity, as reported for synthetic PPAR
gonists (20). A human VCAM-1 promoter-luciferase con-
truct was transiently transfected into BAECs before testing
ioglitazone (3 to 30 M) effects on TNF-induced
CAM-1 promoter-driven luciferase activity. As expected,
NF stimulation significantly induced VCAM-1 promoter
ctivity (8.37  0.58-fold, p  0.05) (Fig. 1D). Pioglitazone
epressed TNF-induced VCAM-1 promoter activity across a
ose range (p  0.05) (Fig. 1D); responses to the PPAR
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sion in a Dose- and Time-Dependent Manner in HSVECs
molecule (VCAM)-1 messenger ribonucleic acid (mRNA) expression was per-
or presence of pioglitazone (PIO) (18 h) at the concentrations shown before
) are provided for comparison. One representative Northern blot (n  3) is
osphate dehydrogenase (GAPDH) mRNA was quantified from the Northern blots
NF vs. TNF alone, Mann-Whitney U test). (C) The time-dependent effects of
Cs using Northern blotting. Results are shown as a percent of the TNF effect
cle on the human VCAM-1 promoter transiently transfected into bovine aortic
the PPAR agonist WY14643 on the VCAM-1 promoter is also shown (right). All
#p  0.05 TNF vs. vehicle; *p  0.05 pioglitazone or WY14643 vs. TNF 

xpres
hesion
sence
00 M
e-3-ph
one/T
HSVE
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fect of
ment,gonist WY14643 are shown for comparison (Fig. 1D).
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Pioglitazone in PPAR Pathways September 2, 2008:869–81ioglitazone regulation of VCAM-1 mRNA expression
n the genetic presence or absence of PPAR. We next
onsidered if pioglitazone’s effects on VCAM-1 required the
enetic presence of PPAR. In Northern blots of microvas-
ular ECs isolated from either wild-type (PPAR/) or
PAR-deficient (PPAR/) mouse hearts, WY14643 (100
M) and pioglitazone (10 M) pre-treatment decreased
CAM-1 mRNA expression in PPAR/ but not in
PAR/ ECs while BRL (1 M) had no effect in either
PAR/ or PPAR/ ECs (Figs. 2A and 2B), as seen in
orthern blotting. Pioglitazone significantly decreased
NF-induced VCAM-1 mRNA expression in a dose-
ependent manner (3 to 30 M, 18 h) in wild-type ECs (as
ompared with TNF stimulation alone, p  0.05) (Fig. 2C)
Figure 2 Pioglitazone Represses TNF-Induced VCAM-1 Expres
Endothelial cells (ECs) isolated from PPAR/ (A) and PPAR/ (B) mouse hea
trations shown (18 h) before mouse TNF stimulation and subsequent to Northern
shown. Northern blotting for VCAM-1 expression was repeated in the presence of t
mice. (E) Quantification of the effects of pioglitazone on VCAM-1 mRNA in PPAR
vehicle; *p  0.05 pioglitazone/TNF vs. TNF alone, Mann-Whitney U test). Abbrut not in PPAR/ ECs (Fig. 2D). Quantification of these Vesponses (n  3) demonstrated a significant VCAM-1 effect
t each pioglitazone dose tested in wild-type but not PPAR-
eficient ECs (p  0.05) (Fig. 2E).
econstitution of PPAR expression in PPAR-
eficient ECs. To test if reconstituting PPAR expression
n PPAR-deficient ECs was sufficient to restore
ioglitazone-mediated repression of VCAM-1 expression,
PAR/ ECs were transiently transfected (24 h) with a
ull-length mouse PPAR cDNA (pSG5 expression vector)
nd compared with cells transfected with the pSG5 vector
lone before pre-treatment with pioglitazone (10 M, 18 h)
r WY14643 (100 M, 18 h) and TNF stimulation.
xpressing PPAR in PPAR/ ECs restored significant
ioglitazone-induced repression of cytokine-induced
in a PPAR-Dependent Manner
re pre-treated with WY14643, rosiglitazone (BRL), or pioglitazone at the concen-
ng for VCAM-1 mRNA and GAPDH expression. One representative blot of 3 is
se range of pioglitazone shown in EC from PPAR/ (C) and PPAR/ (D)
d PPAR/ EC relative to GAPDH mRNA expression (n  3, #p  0.05 TNF vs.
ns as in Figure 1.sion
rts we
blotti
he do
/ an
eviatioCAM-1 expression (Fig. 3A) while transfection of the
p
p
(
e
s
e
P
r
r
P
I
i

s
w
t
r
w
a
B
l
i
r
r
g
m
h
t
d
h
g
g
d
e
a
e
t
o
P
(
p
r
P
z
875JACC Vol. 52, No. 10, 2008 Orasanu et al.
September 2, 2008:869–81 Pioglitazone in PPAR PathwaysSG5 vector alone into PPAR/ ECs had no effect on
ioglitazone responses (Fig. 3B), as evident on densitometry
p  0.05) (Fig. 2C). These results indicate that PPAR
xpression is necessary for pioglitazone-mediated repres-
ion of TNF-induced endothelial VCAM-1 mRNA
xpression.
ioglitazone effects on expression of canonical PPAR-
egulated target genes. We next asked if pioglitazone also
egulated expression in ECs of two other well-established
PAR-regulated targets: acyl-CoA oxidase (ACO) and
B. ACO contains a defined PPAR response element in
ts upstream promoter region (34). Pioglitazone (3 to 30
M) and the PPAR agonist WY14643 (100 M, 6 h)
ignificantly increased ACO mRNA expression compared
ith untreated HSVECs (Fig. 4A). Prior reports indicate
hat PPAR activation increases expression of IB, a key
egulator of inflammation (34). HSVECs were pre-treated
ith pioglitazone (30 M) or WY (100 M, 16 h) either
lone or before TNF stimulation before Western blotting.
oth WY14643 and pioglitazone increased IB protein
evels in HSVECs (Fig. 4B). TNF stimulation further
ncreased the IB response to pioglitazone, as previously
Figure 3 PPAR Is Required for Pioglitazone-Mediated Repress
Northern blot analysis was performed on total RNA isolated from PPAR/ endot
pSG5 alone (B) before stimulation with TNF in either the absence or presence of
expression. (C) Quantification of the VCAM-1 mRNA response to pioglitazone relat
pioglitazone/TNF vs. TNF alone; †p  0.05 WY14643/TNF vs. TNF alone, Ma
tion gradient of pSG5-PPAR as shown before TNF stimulation in either the abse
alone). Abbreviations as in Figure 1.eported for PPAR agonists (Fig. 4B) (35). IPioglitazone’s dependency on PPAR for VCAM-1
epression and its induction of PPAR-regulated target
enes suggests that pioglitazone or one of its metabolites
ight activate PPAR. Prior studies considering this issue
ave varied considerably, with experiments in multiple cell
ypes using PPAR-LBDs from different species (36). Stan-
ard Gal4-LBD transfection assays were performed using
uman PPAR-LBD transfected into BAECs before pio-
litazone (0.01 to 100 M) stimulation. In BAECs, pio-
litazone activated the PPAR-LBD significantly and in a
ose-dependent manner (1 to 100 M) (Fig. 4C). These
ffects were significant although less than the PPAR
ctivation seen with pioglitazone; rosiglitazone had no
ffects on PPAR activation (data not shown). Given cell
ype contributions to variable PPAR-LBD responses previ-
usly reported, we compared pioglitazone effects on human
PAR-LBD assays in NIH/3T3 (fibroblast), HEK293
epithelial), and Hep-G2 (hepatic) cell lines using either
ioglitazone or WY14643 (both 10 M), normalizing
esponses to -galactosidase (pcDNA-Gal) activity.
PAR-LBD activation by either WY14643 or pioglita-
one varied significantly according to cell type (Fig. 4D).
f TNF-Induced Endothelial VCAM-1 mRNA Expression
cells transfected either with PPAR-containing pSG5 overexpression vector (A) or
00 M) or pioglitazone (10 M), with subsequent probing for VCAM-1 or GAPDH
GAPDH mRNA expression levels (n  3, #p  0.05 TNF vs. vehicle; *p  0.05
itney U test). (D) Cells were transfected in panels A and B but with a concentra-
presence of pioglitazone 10 M (n  3, *p  0.05 pioglitazone/TNF vs. TNFion o
helial
WY (1
ive to
nn-Wh
nce ornterestingly, pioglitazone’s PPAR-LBD effects were
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Pioglitazone in PPAR Pathways September 2, 2008:869–81ost potent (relative to WY14643) in bovine ECs (52%)
ompared with all other non-EC cell lines tested: 17% in
IH/3T3 17%, HEK293 21%, and Hep-G2 11% (all p 
.05) (Fig. 4D). Thus, PPAR responses to pioglitazone may
ary depending on cell type.
ioglitazone’s PPAR-dependent effects on hepatic
B protein levels in vivo. We next considered if pio-
litazone regulated PPAR responses in a PPAR-
ependent manner in vivo. Given the TG and sVCAM-1
ffects shown here (Table 1), we focused on pioglitazone
esponses in tissues related to lipid metabolism (liver) and
nflammation (endothelium), and relevant PPAR-
egulated inflammatory target genes in those settings,
amely IB and VCAM-1. PPAR/ (n  4) and
PAR/ (n  4) mice were treated with pioglitazone
gavage, 20mg/kg body weight, 7 days) before harvesting
ivers and performing IB Western blotting. Consistent
ith our in vitro results, pioglitazone significantly increased
epatic IB protein expression in PPAR/ (Fig. 5A)
ut not PPAR/ (Fig. 5B) mice, as evident on densi-
Figure 4 Pioglitazone Induces Known PPAR Target Gene Expr
(A) Northern blot analysis in HSVECs was performed for the PPAR target gene ac
glitazone or WY14643 at the concentrations shown before TNF stimulation. (B) W
g) from HSVECs treated with either pioglitazone (10 M) or WY14643 (250 M)
formed in bovine aortic endothelial cells stimulated with pioglitazone at the concen
were done as before but responses were compared in NIH/3T3 (fibroblasts), HEK2
before stimulation with pioglitazone or WY14643 (both 10 M). Values are expres
lial cells vs. NIH/3T3, **vs. HEK293, ***vs. Hep-G2, both Student t and Mann-Wometry (p  0.05) (Fig. 5C) 1ioglitazone’s PPAR-dependent effect on sVCAM-1
evels in vivo. We next tested if pioglitazone repressed
VCAM-1 levels in mice in vivo in a PPAR-dependent
anner. PPAR/ and PPAR/ mice (9 mice/
enotype/treatment) were treated (daily gavage, 7 days) with
ither pioglitazone (20 mg/kg body weight, 0.5% w/v
ethylcellulose, Group One) or vehicle alone (Group Two)
efore establishing baseline sVCAM-1 levels followed by
PS intraperitoneal stimulation and blood draws. Basal
VCAM-1 levels were significantly higher in PPAR/
ice (847.4 75.1 ng/ml, n 18) versus PPAR/ mice
680.8  42.4 ng/ml, n  18), p  0.007 (Fig. 6). As
xpected, LPS treatment increased sVCAM-1 levels signif-
cantly in vehicle-treated PPAR/ mice (1,058.11 
2.15 ng/ml, n  9, p  0.002). In contrast, LPS-induced
VCAM-1 levels in pioglitazone-treated PPAR/ mice
ere unchanged from basal levels (697.55 33.78 ng/ml, n
, p  0.01, vs. LPS alone, n  9) (Fig. 6). In PPAR/
ice, pioglitazone had no effect on LPS-induced sVCAM-1
rotein levels (pioglitazone, 1,034.8  84.8 ng/ml vs. vehicle,
n and PPAR-LBD Activation in ECs
-oxidase (ACO) and compared with GAPDH in HSVEC pre-treated (16 h) with pio-
n blot analysis for IB expression was performed on total protein extracts (50
stimulation with human TNF. (C) Standard LBD activation assays were per-
ns shown (0.01 to 100 M). (D) PPAR-ligand binding domain (LBD) assays
uman kidney epithelial), Hep-G2 (hepatic), and bovine aortic endothelial cell lines
luciferase/-Gal activity mean  SD (n  3, *p  0.05 bovine aortic endothe-
U tests). Abbreviations as in Figure 1.essio
yl-CoA
ester
before
tratio
93 (h
sed as
hitney,008.5  62.3 ng/ml, n  9) (Fig. 6).
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e present here pre-clinical data that the reportedly
PAR-specific agonist pioglitazone represses inflamma-
ory responses involving endothelial VCAM-1 and hepatic
B in a PPAR-dependent manner both in vitro and in
ivo in mice. Indeed, reconstituting PPAR expression in
PAR-deficient ECs restored pioglitazone-mediated in-
ibition of TNF-induced VCAM-1 expression. To the
est of our knowledge, this is the first demonstration that
efined pioglitazone responses in vivo require the presence
f PPAR. Studies on the role of PPAR in pioglitazone
esponses were prompted by our clinical observations that
ubjects receiving pioglitazone did not demonstrate the
rogressive increase in sVCAM-1 levels seen in a small
ohort of patients with recently diagnosed T2DM receiving
Figure 5 Pioglitazone Induces IB Protein Expression
In Vivo in a PPAR-Dependent Manner
PPAR/ (A) and PPAR/ (B) mice were treated with pioglitazone (20
mg/kg, 7 days via gavage) before livers were harvested and total protein
extracted for Western blot analysis of IB and glyceraldehyde-3-phosphate
dehydrogenase protein levels. Each lane represents a single mouse. (C) The
effects of pioglitazone (solid bars) and vehicle (open bars) on IB protein
expression were quantified and normalized to glyceraldehyde-3-phosphate dehy-
drogenase expression. Mean values  SD are shown (n  4 mice/group. *p
 0.05 pioglitazone vs. vehicle, Mann-Whitney U test).lacebo alone. Repression of cytokine-induced VCAM-1xpression and TG-lowering are well-established PPAR
esponses in humans (37,38). Pre-clinical evidence pre-
ented here that pioglitazone at concentrations overlapping
hose reported in vivo can activate the PPAR-LBD and
nduce expression of PPAR target genes suggests piogli-
azone may directly or indirectly influence PPAR re-
ponses, as previously suggested. Interestingly, PPAR-
BD responses to pioglitazone varied considerably among
ell types and species, with the greatest PPAR activation
vident in EC. This variability may have contributed to
ioglitazone’s characterization as being PPAR-specific
36). Here we have extended prior observations by demon-
trating that specific pioglitazone effects in vivo are absent in
he PPAR-deficient mouse. Together these findings have
otential implications for TZD mechanisms of action,
nterpreting TZD studies, especially in pre-clinical models
s well as the development of novel PPAR therapeutic
gents.
Agonists for the same PPAR isoform can differ signifi-
antly in their biologic and clinical effects. In transcriptional
rofiling and proteomic assays, different PPAR agonists
ave both shared and distinct gene expression patterns
39–41). Clinically, both pioglitazone and rosiglitazone
ack the irreversible liver failure seen with troglitazone, the
rst clinically approved PPAR agonist (42). In a head-to-
ead clinical trial, pioglitazone decreased TG significantly
hile rosiglitazone did not (11), as also suggested by
eta-analysis data (43). Although the contribution of dif-
Figure 6 Pioglitazone Decreases LPS-Induced Soluble VCAM-1
in PPAR/ But Not PPAR/ Mice In Vivo
PPAR/ and PPAR/ mice were treated with pioglitazone or vehicle alone
before lipopolysacharide (LPS) injection (n  9/genotype as in Methods sec-
tion). Soluble vascular adhesion molecule-1 (sVCAM-1) levels in PPAR/ and
PPAR/ mice are shown at baseline (*p  0.007 PPAR/ vs. PPAR/
mice) and after LPS injection in mice treated with either vehicle or pioglitazone
(PIO) (PPAR/, n  9, #p  0.002 LPS/vehicle vs. vehicle; ‡p  0.01 piogli-
tazone/LPS vs. vehicle/LPS) and in PPAR/ mice (n  9, †p  0.05 vehi-
cle/LPS vs. vehicle; [p  NS] nonsignificant pioglitazone/LPS vs. vehicle/LPS,
significance determined using Mann-Whitney U test). The mean serum sVCAM-1
concentration of each group  SD is shown.
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Pioglitazone in PPAR Pathways September 2, 2008:869–81erential TZD effects to cardiovascular events remains
nclear, our data identify an additional biologic mechanism
hat may be involved in pioglitazone responses. Consider-
ble evidence establishes TZDs as limiting inflammation
nd atherosclerosis in mouse models (45). In clinical studies,
oth pioglitazone and rosiglitazone lower C-reactive protein
38,46–49), anatomic indicators like carotid intimal medial
hickness (49–53), and vessel reactivity (54). In the pro-
pective PROactive (PROspective pioglitAzone Clinical
rial In macroVascular Events) study, pioglitazone did not
ecrease a large, combined primary cardiovascular end point
lthough a secondary clinical end point of stroke, myocar-
ial infarction, and cardiovascular death was improved (55).
arious logistical factors have been speculated as contribu-
ors to the study’s negative primary end point (4). Recently,
n the PERISCOPE (Pioglitazone Effect on Regression of
ntravascular Sonographic Coronary Obstruction Prospec-
ive Evaluation) trial, progression of atherosclerosis was seen
n coronary intravascular ultrasound in otherwise well-
reated patients randomized to glimiperide but not in those
eceiving pioglitazone (56). Pioglitazone significantly de-
reased TG and raised HDL in both the PROactive and
ERISCOPE trials. No large prospective clinical cardio-
ascular rosiglitazone trial data is currently available. Recent
eta-analyses have raised concern over a possible increase in
ardiovascular risk with rosiglitazone (12–14,55), although
ith limitations in this data as raised by the authors and
thers (15,55). In similar meta-analyses, no increased risk
ith pioglitazone was found (13). Given changes induced
y TZDs on surrogate markers for cardiovascular disease in
asic and clinical studies, it remains possible that offsetting
dverse cardiovascular effects could exist with these agents.
PAR activation can increase homocysteine levels and
erum creatinine levels (57–60). While the VA-HIT (Vet-
rans Affairs High-Density Lipoprotein Cholesterol Inter-
ention Trial) study did show decreased cardiovascular
vents with the putative PPAR agonist gemfibrozil, in the
IELD (Fenofibrate Intervention and Event Lowering in
iabetes) study, fenofibrate, a more potent PPAR agonist,
id not show a difference in the primary cardiovascular end
oint (61,62). Although the role of pioglitazone-mediated
PAR activation in determining clinical responses remains
nclear, our data suggest at the very least that PPAR
ctivation should be considered in interpreting basic science
ata with this agent.
Both VCAM-1 and IB regulate inflammatory re-
ponses in atherosclerosis. Endothelial VCAM-1 expression
s an important early atherogenic step (2). Circulating levels
f VCAM-1 may predict subsequent clinical cardiovascular
vents (63) while VCAM-1 may be elevated in T2DM,
erhaps as a result of the hypertriglyceridemia and/or low
DL cholesterol (35,64,65). Reducing TG levels with
brates or fish oil, both of which can be considered PPAR
ctivators (66,67), reportedly decreases soluble adhesion
olecule levels (35,67,68). VCAM-1 expression is con-rolled by multiple pathways, including NF-B and PPAR t69,70). In vitro, VCAM-1 repression has been reported by
ome PPAR agonists but not others, and at drug concen-
rations that may have PPAR-independent effects (31–33).
lthough we found PPAR agonists repressed VCAM-1 in
ild-type but not PPAR-deficient ECs, rosiglitazone and
5d-PGJ2 had no VCAM-1 effects (21). Differences among
eports of PPAR agonist VCAM-1 effects may involve
ifferences among agents or the cell types under study.
NF-B activation, which is inhibited by IB, increases
CAM-1 expression. PPAR activation induces IB
35). Here we found that pioglitazone increased IB
xpression in a PPAR-dependent manner in HSVECs in
itro and in liver in vivo; 15 deoxyprostaglandin J2 and
roglitazone increase IB expression but independent of
PAR (71–73). The more selective PPAR ligand rosigli-
azone did not change IB expression in human mono-
yte/macrophages (73,74). In contrast, pioglitazone report-
dly increased IB levels in peripheral mononuclear cells
n human subjects (75). These results are potentially con-
istent with pioglitazone exerting effects through PPAR as
lso suggested by studies in which pioglitazone treatment
ncreased expression of PPAR target genes in subcutaneous
at (44). The possibility that these responses derived from
ioglitazone activation of PPAR was not discussed (44).
PPAR biology suggests several mechanisms for how
gonists for the same PPAR isotype might exert distinct
ffects. PPARs have a particularly large LBD, even as
ompared with other nuclear receptors (76). PPAR activa-
ion induces a conformational change in the AF2 domain,
hich allows coactivator recruitment, corepressor release,
nd formation of the heterodimeric PPAR-RXR complex.
hese critical determinants of transcriptional responses can
ary as a function of different interactions between structur-
lly distinct PPAR agonists and the large PPAR-LBD
76). Interestingly, other in vitro pharmacologic studies also
uggest pioglitazone may activate PPAR (36). Recently,
igand-independent mechanisms influencing PPAR-
ediated anti-inflammatory effects have been reported, for
xample through SUMOylation (Small Ubiquitin-related
odifier) (77,78). Differences among PPAR-interacting
olecules underlie the concept of selective nuclear receptor
odulators, as has been raised for the estrogen receptor and
ovel PPAR agents in development (79,80). The potential
ariability among specific PPAR-interacting molecules is
pparent in the reports of full agonists, selective partial
gonists, inverse agonists, antagonists, as well as pan-PPAR
nd dual PPAR agonists (80–83).
Dual PPAR/ agonists offered the putative clinical
enefits of combining HDL-raising/TG-lowering via
PAR with improved insulin sensitivity through PPAR
80). No dual PPAR/ agonists have yet been approved
or use (84). Muraglitazar and tesaglitazar reached late stage
esting before being abandoned due to adverse effects,
ncluding increased cardiovascular events (85,86), raising
oncerns over dual PPAR/ agonists as a drug class. Given
he evidence that pioglitazone can be used safely (13), our
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September 2, 2008:869–81 Pioglitazone in PPAR Pathwaysata that pioglitazone may act, at least in part, through
PAR suggest that selective modulators targeting both
PAR and - may be able to be safely developed.
oreover, our findings suggest pioglitazone’s description as
 PPAR-specific agonist may need revisiting. Further
tudies would need to include analysis of pioglitazone’s
etabolites with biologic activity but unknown PPAR
electivity (87,88). Pioglitazone metabolite production may
iffer depending on cell types, tissues, species, or genetic
ariants. Although pioglitazone demonstrates more potent
BD activation of PPAR than PPAR, the PPAR-
BD activation seen is within a range that could influence
iologic responses, especially in EC. LBD activation may
lso underestimate functional PPAR effects in vivo as a
esult of mechanisms such as preferential generation, stabi-
ization, or transport of a specific drug metabolite.
Pioglitazone could also regulate PPAR target genes
ndirectly, for example altering PPAR regulatory proteins
r inducing the formation of endogenous PPAR agonists.
or example, lipoprotein lipase (LPL), a positively regulated
PAR target gene, can generate PPAR ligands through
LDL hydrolysis (22). Increased LPL expression and
ctivity would be associated with lower TG and higher
DL, as occurs with gain of function LPL polymorphisms
nd after treatment with synthetic PPAR agonists (66,89).
rior work identifies increased LPL-mediated lipolysis as a
ontributor to pioglitazone’s TG-lowering effects (90). In
linical studies, pioglitazone induces LPL expression and
lso decreases the natural LPL inhibitor apoCIII (44,90),
urther supporting possible indirect PPAR  activation
hrough increased VLDL hydrolysis. Since both LPL and
poCIII are PPAR-regulated target genes, positive feed-
orward mechanisms may amplify these effects (22,91).
Independent of a direct or indirect mechanism, PPAR
s required in order for VCAM-1 repression and IB
nduction to occur in vitro and in vivo in mice, which
xpands potential mechanisms of action for this agent, at
east in vitro and in mouse models. This data also under-
cores the need to fully understand the effects of both
xisting and emerging PPAR agonists and their biologically
ctive metabolites. Indeed, the complexity of PPAR biol-
gy, the number of variables dictating transcriptional and,
ence, clinical responses, and the fact that agonist structure
an determine biologic response argues that the notion of
eneral PPAR-activating drug classes may be limited.
cknowledgment
he authors thank Ruzena Tupy for excellent editorial
ssistance.
eprint requests and correspondence: Dr. Jorge Plutzky, Brigham
nd Women’s Hospital, 77 Avenue Louis Pasteur, NRB 742, Boston,assachusetts 02115. E-mail: jplutzky@rics.bwh.harvard.edu.EFERENCES
1. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell
2001;104:503–16.
2. Libby P. Current concepts of the pathogenesis of the acute coronary
syndromes. Circulation 2001;104:365–72.
3. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest
2006;116:1813–22.
4. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as
transcriptional nodal points and therapeutic targets. Circulation 2007;
115:518–33.
5. Lindberg M, Astrup A. The role of glitazones in management of type
2 diabetes. A dream or a nightmare? Obes Rev 2007;8:381–4.
6. Tontonoz P, Hu E, Spiegelman BM. Regulation of adipocyte gene
expression and differentiation by peroxisome proliferator activated
receptor gamma. Curr Opin Genet Dev 1995;5:571–6.
7. Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity
relationship between peroxisome proliferator-activated receptor
gamma agonism and the antihyperglycemic activity of thiazolidinedio-
nes. J Med Chem 1996;39:665–8.
8. Thomson PDR Healthcare. Physicians Desk Reference. 61st edition.
Seattle, WA: Thomson PDR Healthcare, 2007.
9. Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-
activated receptor gamma agonists: their role as vasoprotective agents
in diabetes. Endocrinol Metab Clin North Am 2006;35:561–74.
0. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:
1106 –18.
1. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid
and glycemic effects of pioglitazone and rosiglitazone in patients with
type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547–54.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med
2007;356:2457–71.
3. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk
of cardiovascular events in patients with type 2 diabetes mellitus: a
meta-analysis of randomized trials. JAMA 2007;298:1180–8.
4. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular
events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189–95.
5. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the
risk for myocardial infarction and cardiovascular death. Ann Intern
Med 2007;147:578–81.
6. Krall RL. Cardiovascular safety of rosiglitazone. Lancet 2007;369:
1995–6.
7. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention
of macrovascular events in patients with type 2 diabetes in the
PROactive study (PROspective pioglitAzone Clinical Trial In macro-
Vascular Events): a randomised controlled trial. Lancet 2005;366:
1279–89.
8. Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR-
alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am J
Ther 2007;14:49–62.
9. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety
issues and prospects for future generations of PPAR modulators.
Biochim Biophys Acta 2007;177:1065–81.
0. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis.
Arterioscler Thromb Vasc Biol 2007;27:2292–301.
1. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR-alpha
activators inhibit cytokine-induced vascular cell adhesion molecule-1
expression in human endothelial cells. Circulation 1999;99:3125–31.
2. Ziouzenkova O, Perrey S, Marx N, Bacqueville D, Plutzky J. Perox-
isome proliferator-activated receptors. Curr Atheroscler Rep 2002;4:
59–64.
3. Lee SS, Gonzalez FJ. Targeted disruption of the peroxisome
proliferator-activated receptor alpha gene, PPAR alpha. Ann N Y
Acad Sci 1996;804:524–9.
4. Hamdy O, Ledbury S, Mullooly C, et al. Lifestyle modification
improves endothelial function in obese subjects with the insulin
resistance syndrome. Diabetes Care 2003;26:2119–25.
5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent
clinical trials for the National Cholesterol Education Program Adult
Treatment Panel III guidelines. J Am Coll Cardiol 2004;44:720–32.
6. Tseng KH. Standards of medical care in diabetes—2006. Diabetes
Care 2006;29 Suppl 1:S4–42.
22
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
880 Orasanu et al. JACC Vol. 52, No. 10, 2008
Pioglitazone in PPAR Pathways September 2, 2008:869–817. Ziouzenkova O, Perrey S, Asatryan L, et al. Lipolysis of triglyceride-
rich lipoproteins generates PPAR ligands: evidence for an antiinflam-
matory role for lipoprotein lipase. Proc Natl Acad Sci U S A
2003;100:2730–5.
8. Ahmed W, Orasanu G, Nehra V, et al. High-density lipoprotein
hydrolysis by endothelial lipase activates PPAR-alpha: a candidate
mechanism for high-density lipoprotein-mediated repression of leu-
kocyte adhesion. Circ Res 2006;98:490–8.
9. Report of the expert committee on the diagnosis and classification of
diabetes mellitus. Diabetes Care 2003;26:S5–20.
0. Eckland D, Danhof M. Clinical pharmacokinetics of pioglitazone.
Exp Clin Endocrinol Diabetes 2000;108 Suppl 2:S234–42.
1. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-
activated receptor activators target human endothelial cells to inhibit
leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol
1999;19:2094–104.
2. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK.
Peroxisome proliferator-activated receptor gamma ligands inhibit de-
velopment of atherosclerosis in LDL receptor-deficient mice. J Clin
Invest 2000;106:523–31.
3. Rival Y, Beneteau N, Taillandier T, et al. PPAR-alpha and PPAR-
delta activators inhibit cytokine-induced nuclear translocation of
NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.
Eur J Pharmacol 2002;435:143–51.
4. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W.
Control of the peroxisomal beta-oxidation pathway by a novel family
of nuclear hormone receptors. Cell 1992;68:879–87.
5. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBal-
pha expression as a mechanism contributing to the anti-inflammatory
activities of peroxisome proliferator-activated receptor-alpha activa-
tors. J Biol Chem 2000;275:36703–7.
6. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human
peroxisome proliferator-activated receptor (PPAR-) subtypes by pio-
glitazone. Biochem Biophys Res Commun 2000;278:704–11.
7. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER.
Fenofibrate and pioglitazone improve endothelial function and reduce
arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007;
194:e123–30.
8. Takase H, Nakazawa A, Yamashita S, et al. Pioglitazone produces
rapid and persistent reduction of vascular inflammation in patients
with hypertension and type 2 diabetes mellitus who are receiving
angiotensin II receptor blockers. Metabolism 2007;56:559–64.
9. Gao J, Ann Garulacan L, Storm SM, et al. Identification of in vitro
protein biomarkers of idiosyncratic liver toxicity. Toxicol In Vitro
2004;18:533–41.
0. Bottoni P, Giardina B, Martorana GE, et al. A two-dimensional
electrophoresis preliminary approach to human hepatocarcinoma dif-
ferentiation induced by PPAR–agonists. J Cell Mol Med 2005;9:
462–7.
1. Guo L, Zhang L, Sun Y, et al. Differences in hepatotoxicity and gene
expression profiles by anti-diabetic PPAR gamma agonists on rat
primary hepatocytes and human HepG2 cells. Mol Divers 2006;10:
349–60.
2. Johnson MD, Campbell LK, Campbell RK. Troglitazone: review and
assessment of its role in the treatment of patients with impaired
glucose tolerance and diabetes mellitus. Ann Pharmacother 1998;32:
337–48.
3. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the
effect of thiazolidinediones on cardiovascular risk factors. Arch Intern
Med 2004;164:2097–104.
4. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on
peroxisome proliferator-activated receptor-gamma target genes related
to lipid storage in vivo. Diabetes Care 2004;27:1660–7.
5. Plutzky J. Peroxisome proliferator-activated receptors in endothelial
cell biology. Curr Opin Lipidol 2001;12:511–8.
6. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K,
Freed MI. Effect of rosiglitazone treatment on nontraditional markers
of cardiovascular disease in patients with type 2 diabetes mellitus.
Circulation 2002;106:679–84.
7. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a
peroxisome proliferator-activated receptor-gamma agonist, on markers
of endothelial cell activation, C-reactive protein, and fibrinogen levels
in non-diabetic coronary artery disease patients. J Am Coll Cardiol
2003;42:1757–63.8. Plutzky J. Peroxisome proliferator-activated receptors as therapeutic
targets in inflammation. J Am Coll Cardiol 2003;42:1764–6.
9. Yoshimoto T, Naruse M, Shizume H, et al. Vasculo-protective effects
of insulin sensitizing agent pioglitazone in neointimal thickening and
hypertensive vascular hypertrophy. Atherosclerosis 1999;145:333–40.
0. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura
Y. Rapid communication: inhibitory effect of pioglitazone on carotid
arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab
2001;86:3452–6.
1. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on
common carotid intima-media thickness progression in coronary artery
disease patients without diabetes mellitus. Arterioscler Thromb Vasc
Biol 2004;24:930–4.
2. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone
compared with glimepiride on carotid intima-media thickness in type
2 diabetes: a randomized trial. JAMA 2006;296:2572–81.
3. Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosigli-
tazone and carotid IMT progression rate in a mixed cohort of patients
with type 2 diabetes and the insulin resistance syndrome: main results
from the Rosiglitazone Atherosclerosis study. J Intern Med 2007;261:
293–305.
4. Dandona P, Aljada A, Chaudhuri A. Vascular reactivity and thiazo-
lidinediones. Am J Med 2003;115:81S–6S.
5. Lago RM, Singh PP, Nesto RW. Congestive heart failure and
cardiovascular death in patients with prediabetes and type 2 diabetes
given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lancet 2007;370:1129–36.
6. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone
vs glimepiride on progression of coronary atherosclerosis in patients
with type 2 diabetes: the PERISCOPE randomized controlled trial.
JAMA 2008;299:1561–73.
7. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after
therapy with fenofibrate or bezafibrate. Lancet 1999;554:219–20.
8. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in
renal function associated with fibrate therapy. Clin Nephrol 2001;55:
39–44.
9. Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P. Fenofibrate
increases homocystinemia through a PPAR-alpha-mediated mecha-
nism. J Cardiovasc Pharmacol 2004;43:452–3.
0. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety
considerations with fibrate therapy. Am J Cardiol 2007;99:3C–18C.
1. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary
prevention of coronary heart disease in men with low levels of
high-density lipoprotein cholesterol. Veterans Affairs High-Density
Lipoprotein Cholesterol Intervention Trial Study Group. N Engl
J Med 1999;341:410–8.
2. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate
therapy on cardiovascular events in 9795 people with type 2 diabetes
mellitus (the FIELD study): randomised controlled trial. Lancet
2005;366:1849–61.
3. Mulvihill NT, Foley JB, Crean P, Walsh M. Prediction of cardiovas-
cular risk using soluble cell adhesion molecules. Eur Heart J 2002;23:
1569–74.
4. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules
in hypertriglyceridemia and potential significance on monocyte adhe-
sion. Arterioscler Thromb Vasc Biol 1998;18:723–31.
5. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C,
Franceschini G. Elevated soluble cellular adhesion molecules in
subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol
2002;22:656–61.
6. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated
receptor alpha in metabolic disease, inflammation, atherosclerosis and
aging. Curr Opin Lipidol 1999;10:151–9.
7. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN.
Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial
interactions through activation of PPAR-alpha. Blood 2002;100:
1340–6.
8. Okapcova J, Gabor D. The levels of soluble adhesion molecules in
diabetic and nondiabetic patients with combined hyperlipoproteinemia
and the effect of ciprofibrate therapy. Angiology 2004;55:629–39.
9. Xu X, Otsuki M, Saito H, et al. PPAR-alpha and GR differentially
down-regulate the expression of nuclear factor-kappaB-responsive
genes in vascular endothelial cells. Endocrinology 2001;142:3332–9.
77
7
7
7
7
7
7
7
7
8
8
8
8
8
8
8
8
8
8
9
9
K
F
s
g
N
o
d
881JACC Vol. 52, No. 10, 2008 Orasanu et al.
September 2, 2008:869–81 Pioglitazone in PPAR Pathways0. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and athero-
sclerosis. Atherosclerosis 2003;170:191–203.
1. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone
prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000;
403:103–8.
2. Ward C, Dransfield I, Murray J, Farrow SN, Haslett C, Rossi AG.
Prostaglandin D2 and its metabolites induce caspase-dependent gran-
ulocyte apoptosis that is mediated via inhibition of I kappa B alpha
degradation using a peroxisome proliferator-activated receptor-
gamma-independent mechanism. J Immunol 2002;168:6232–43.
3. Guyton K, Bond R, Reilly C, Gilkeson G, Halushka P, Cook J.
Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a
peroxisome proliferator-activated receptor gamma agonist on macro-
phage activation. J Leukoc Biol 2001;69:631–8.
4. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent
antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab
2004;89:2728–35.
5. Klotz L, Schmidt M, Giese T, et al. Proinflammatory stimulation and
pioglitazone treatment regulate peroxisome proliferator-activated re-
ceptor gamma levels in peripheral blood mononuclear cells from
healthy controls and multiple sclerosis patients. J Immunol 2005;175:
4948–55.
6. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs:
from orphan receptors to drug discovery. J Med Chem 2000;527–
50.
7. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent
pathway mediates transrepression of inflammatory response genes by
PPAR–gamma. Nature 2005;437:759–63.
8. Ghisletti S, Huang W, Ogawa S, et al. Parallel SUMOylation-
dependent pathways mediate gene- and signal-specific transrepression
by LXRs and PPAR-gamma. Mol Cell 2007;25:57–70.
9. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen
receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295:
431–7.
0. Fievet C, Fruchart JC, Staels B. PPAR-alpha and PPAR-gamma dual
agonists for the treatment of type 2 diabetes and the metabolic
syndrome. Curr Opin Pharmacol 2006;6:606–14.
1. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-
gamma calls for activation in moderation: lessons from genetics and
pharmacology. Endocr Rev 2004;25:899–918.
2. Seimandi M, Lemaire G, Pillon A, et al. Differential responses of
PPARalpha, PPARdelta, and PPARgamma reporter cell lines to
selective PPAR synthetic ligands. Anal Biochem 2005;344:8–15. a3. Hamuro Y, Coales SJ, Morrow JA, et al. Hydrogen/deuterium-
exchange (H/D-Ex) of PPAR-gamma LBD in the presence of various
modulators. Protein Sci 2006;15:1883–92.
4. Henke BR. Peroxisome proliferator-activated receptor alpha/gamma
dual agonists for the treatment of type 2 diabetes. J Med Chem
2004;47:4118–27.
5. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and
major adverse cardiovascular events in patients with type 2 diabetes
mellitus. JAMA 2005;294:2581–6.
6. Hellmold H, Zhang H, Andersson U, et al. Tesaglitazar, a PPAR-
alpha/gamma agonist, induces interstitial mesenchymal cell DNA
synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci
2007;98:63–74.
7. Lin ZJ, Ji W, Desai-Krieger D, Shum L. Simultaneous determination
of pioglitazone and its two active metabolites in human plasma by
LC-MS/MS. J Pharm Biomed Anal 2003;33:101–8.
8. Shen Z, Reed JR, Creighton M, et al. Identification of novel
metabolites of pioglitazone in rat and dog. Xenobiotica 2003;33:
499 –509.
9. Wang XL, McCredie RM, Wilcken DE. Common DNA polymor-
phisms at the lipoprotein lipase gene. Association with severity of
coronary artery disease and diabetes. Circulation 1996;96:1339–45.
0. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPAR-
gamma agonist pioglitazone on lipoprotein metabolism in patients
with type 2 diabetes mellitus. J Clin Invest 2005;115:1323–32.
1. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate
apolipoprotein C-III expression independent of induction of peroxi-
somal acyl coenzyme A oxidase. A potential mechanism for the
hypolipidemic action of fibrates. J Clin Invest 1995;95:705–12.
ey Words: inflammation y VCAM-1 y PPAR.
APPENDIX
or a supplementary table on the impact of various baseline parameters on
VCAM-1 changes and the sVCAM-1 levels in pioglitazone versus placebo
roups after controlling for age, as well as a supplementary figure on
orthern blot analysis of PPAR mRNA expression and the quantification
f PPAR expression levels by quantitative RT-PCR after concentration-
ependent PPAR transfection, please see the online version of this
rticle.
